To: John Howard, MD, MPH, JD, LLM, MBA, NIOSH Docket Office
"We support the intent behind NIOSH’s Hazardous Drug List of keeping workers safe from unnecessary harm, but do not believe that available evidence points to a need for the inclusion of liraglutide. Therefore, we respectfully ask that you remove the drug from the list. "
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.